| Features: | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Hibiscus sabdariffa (commonly known as Roselle) It is rich in bioactive components such as polyphenols, anthocyanins, flavonoids, organic acids, and other antioxidants. Hibiscus sabdariffa is rich in antioxidants and bioactive compounds that show potential anti-cancer effects by reducing oxidative stress, inhibiting cell proliferation, inducing apoptosis, and modulating inflammatory pathways.
Hibiscus sabdariffa — commonly known as roselle, is an edible medicinal plant whose calyces and leaves contain anthocyanins, polyphenols, flavonoids, phenolic acids, and organic acids. It is classified as a botanical food/nutraceutical and plant-extract modality rather than a defined anticancer drug. Standard abbreviations include HS and H. sabdariffa. The calyx is the predominant food and beverage source, whereas several anticancer studies have used leaf extracts, anthocyanin-rich fractions, or polyphenol-enriched preparations that are not compositionally equivalent to ordinary hibiscus tea. Important constituents include delphinidin-3-sambubioside, cyanidin-3-sambubioside, protocatechuic acid, and other polyphenols. -Calyx — the thick, fleshy red structure surrounding the base of the flower and later the seed capsule. This is the main material used for hibiscus tea, beverages, extracts, and most commercial supplements. It is especially rich in anthocyanins, organic acids, and polyphenols. Primary mechanisms (ranked):
Bioavailability / PK relevance: Hibiscus anthocyanins are orally absorbed but have low systemic bioavailability and are rapidly metabolized and eliminated. Human pharmacokinetic studies demonstrate circulating anthocyanin-derived compounds after oral Hibiscus extract, but exposure to intact parent anthocyanins is substantially lower than concentrations commonly used in mechanistic cell-culture studies. Extract composition, plant part, cultivar, processing, and extraction method materially affect exposure. In-vitro vs systemic exposure relevance: Many anticancer experiments use approximately hundreds of µg/mL to mg/mL of crude or polyphenol-enriched extract, or high-µM to millimolar concentrations of individual phenolic compounds. These concentrations generally exceed plausible circulating concentrations following ordinary dietary Hibiscus consumption. Direct translation of in-vitro anticancer potency to oral tea or supplement use is therefore poor. Local gastrointestinal exposure may be considerably higher than systemic exposure. Clinical evidence status: Cancer evidence is predominantly preclinical, consisting of cell-culture studies and limited animal models; there is no established human anticancer efficacy and no validated Hibiscus anticancer dosing regimen. Human RCT evidence is considerably stronger for blood-pressure reduction and some cardiometabolic effects than for cancer treatment. Hibiscus should therefore be categorized as preclinical for anticancer therapy, not as an established cancer adjunct. Oral Hibiscus preparations are generally well tolerated in short-term human studies, but clinically relevant hypotensive and glucose-lowering effects can occur, creating potential additive effects with antihypertensive or antidiabetic therapy. Hibiscus sabdariffa Cancer-Relevant Mechanisms
P: 0–30 min R: 30 min–3 hr G: >3 hr |
| Source: |
| Type: |
| Tumor cell invasion is a critical process in cancer progression and metastasis, where cancer cells spread from the primary tumor to surrounding tissues and distant organs. This process involves several key steps and mechanisms: 1.Epithelial-Mesenchymal Transition (EMT): Many tumors originate from epithelial cells, which are typically organized in layers. During EMT, these cells lose their epithelial characteristics (such as cell-cell adhesion) and gain mesenchymal traits (such as increased motility). This transition is crucial for invasion. 2.Degradation of Extracellular Matrix (ECM): Tumor cells secrete enzymes, such as matrix metalloproteinases (MMPs), that degrade the ECM, allowing cancer cells to invade surrounding tissues. This degradation facilitates the movement of cancer cells through the tissue. 3.Cell Migration: Once the ECM is degraded, cancer cells can migrate. They often use various mechanisms, including amoeboid movement and mesenchymal migration, to move through the tissue. This migration is influenced by various signaling pathways and the tumor microenvironment. 4.Angiogenesis: As tumors grow, they require a blood supply to provide nutrients and oxygen. Tumor cells can stimulate the formation of new blood vessels (angiogenesis) through the release of growth factors like vascular endothelial growth factor (VEGF). This not only supports tumor growth but also provides a route for cancer cells to enter the bloodstream. 5.Invasion into Blood Vessels (Intravasation): Cancer cells can invade nearby blood vessels, allowing them to enter the circulatory system. This step is crucial for metastasis, as it enables cancer cells to travel to distant sites in the body. 6.Survival in Circulation: Once in the bloodstream, cancer cells must survive the immune response and the shear stress of blood flow. They can form clusters with platelets or other cells to evade detection. 7.Extravasation and Colonization: After traveling through the bloodstream, cancer cells can exit the circulation (extravasation) and invade new tissues. They may then establish secondary tumors (metastases) in distant organs. 8.Tumor Microenvironment: The surrounding microenvironment plays a significant role in tumor invasion. Factors such as immune cells, fibroblasts, and signaling molecules can either promote or inhibit invasion and metastasis. |
| 7359- | HibSad, | Novel Insight into the Cellular and Molecular Signalling Pathways on Cancer Preventing Effects of Hibiscus sabdariffa: A Review - PubMed |
| - | Review, | Var, | NA |
| 7355- | HibSad, | Evaluation of antitumoral effect of Hibiscus sabdariffa extract on human breast cancer cells |
| - | in-vitro, | BC, | MCF7 | - | in-vitro, | BC, | MDA-MB-231 |
Query results interpretion may depend on "conditions" listed in the research papers. Such Conditions may include : -low or high Dose -format for product, such as nano of lipid formations -different cell line effects -synergies with other products -if effect was for normal or cancerous cells
Filter Conditions: Pro/AntiFlg:% IllCat:% CanType:% Cells:% prod#:263 Target#:324 State#:% Dir#:%
wNotes=0 sortOrder:rid,rpid